RAM
VRDN icon

Riggs Asset Management’s Viridian Therapeutics VRDN Stock Holding History

Riggs Asset Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-43
Closed -$602 – 846
2025
Q2 		$602 Buy
+43
New +$584 ﹤0.01% 823

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Riggs Asset Management's VRDN Position: Q3 2025 in Review

Riggs Asset Management sold out of Viridian Therapeutics (VRDN) in Q3 2025, closing a stake of 43 shares — an estimated $602 sold.

Riggs Asset Management first reported a position in VRDN in Q2 2025 and held it in 1 quarter. The position peaked at $602 in Q2 2025. 169 funds tracked by Wall St. Rank hold VRDN as of Q3 2025.

  • Riggs Asset Management reported no remaining Viridian Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Riggs Asset Management sold 43 Viridian Therapeutics shares in Q3 2025, an estimated $602.
  • Riggs Asset Management first reported a position in Viridian Therapeutics in Q2 2025 and held it in 1 quarter.
  • Riggs Asset Management's Viridian Therapeutics position peaked at $602 in Q2 2025.
  • 169 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2025.

Based on Riggs Asset Management's 13F filing for Q3 2025, filed 13 Nov 2025.